Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Sponsor
Shanghai Chest Hospital
Study ID
NCT03913182
Phase
PHASE2
Status
Unknown

Conditions

  • Apatinib
  • Esophageal Squamous Cell Carcinoma
  • Metastasis
  • Recurrence

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

It was difficult to obtain clinical benefits through traditional chemotherapy and radiotherapy for the patients who have recurrence or metastasis tumor even though they have received first-line chemotherapy or combined radiotherapy before, but failed.The aim of this study was to evaluate the safety and efficacy of apatinib, an anti-angiogenesis drug, in the treatment of patients with advanced esophageal squamous cell carcinoma who had recurrence or metastasis after radical resection

Key Dates

Start date
Apr 2, 2019
Status verified
Feb 2020
Primary completion
May 30, 2020
Completion
May 30, 2021

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib group
    apatinib：500mg po Qd

Primary Outcome Measure

PFS [ Time Frame: 2.5 months ]

Central Contacts

Related Studies